A retrospective study investigating efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumors
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Everolimus (Primary) ; Sunitinib (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions; Therapeutic Use
- 06 Dec 2016 New trial record
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress